| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6838464 | VIIV HLTHCARE | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(3 years ago) | |
| US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(1 year, 14 days ago) | |
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(11 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(2 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(3 years from now) | |
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(7 years from now) | |
Cabenuva Kit is owned by Viiv Hlthcare.
Cabenuva Kit contains Cabotegravir; Rilpivirine.
Cabenuva Kit has a total of 7 drug patents out of which 2 drug patents have expired.
Expired drug patents of Cabenuva Kit are:
- US6838464
- US8080551
Cabenuva Kit was authorised for market use on 21 January, 2021.
Cabenuva Kit is available in suspension, extended release;intramuscular dosage forms.
Cabenuva Kit can be used as treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy, treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg.
Drug patent challenges can be filed against Cabenuva Kit from 21 January, 2025.
The generics of Cabenuva Kit are possible to be released after 15 September, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Dosing Schedule(D-184) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT family patents
